Masimo Valuation

Is MASI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MASI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MASI ($138.83) is trading below our estimate of fair value ($302.45)

Significantly Below Fair Value: MASI is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MASI?

Other financial metrics that can be useful for relative valuation.

MASI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4x
Enterprise Value/EBITDA38.5x
PEG Ratio3.7x

Price to Earnings Ratio vs Peers

How does MASI's PE Ratio compare to its peers?

The above table shows the PE ratio for MASI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.3x
ITGR Integer Holdings
41.1x21.2%US$4.3b
PODD Insulet
40.7x2.4%US$16.1b
TFX Teleflex
42.6x21.3%US$11.3b
DXCM DexCom
40.9x16.5%US$27.3b
MASI Masimo
93.5x25.1%US$7.4b

Price-To-Earnings vs Peers: MASI is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the peer average (41.3x).


Price to Earnings Ratio vs Industry

How does MASI's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.5%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: MASI is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the US Medical Equipment industry average (37.1x).


Price to Earnings Ratio vs Fair Ratio

What is MASI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MASI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio93.5x
Fair PE Ratio39x

Price-To-Earnings vs Fair Ratio: MASI is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the estimated Fair Price-To-Earnings Ratio (39x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MASI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$138.83
US$152.02
+9.5%
11.3%US$170.00US$125.00n/a7
Sep ’25US$117.52
US$155.00
+31.9%
9.2%US$170.00US$125.00n/a7
Aug ’25US$107.33
US$155.72
+45.1%
8.9%US$170.00US$125.00n/a7
Jul ’25US$116.40
US$155.72
+33.8%
8.9%US$170.00US$125.00n/a7
Jun ’25US$124.50
US$151.89
+22.0%
11.3%US$170.00US$125.00n/a7
May ’25US$134.01
US$150.60
+12.4%
12.5%US$170.00US$117.00n/a8
Apr ’25US$144.83
US$146.89
+1.4%
12.5%US$166.00US$117.00n/a7
Mar ’25US$126.49
US$128.33
+1.5%
9.4%US$145.00US$117.00n/a6
Feb ’25US$133.32
US$119.17
-10.6%
20.1%US$145.00US$70.00n/a6
Jan ’25US$117.21
US$92.00
-21.5%
15.4%US$110.00US$70.00n/a7
Dec ’24US$96.71
US$92.00
-4.9%
15.4%US$110.00US$70.00n/a7
Nov ’24US$78.57
US$130.63
+66.3%
10.9%US$150.00US$110.00n/a8
Oct ’24US$87.68
US$128.50
+46.6%
11.2%US$150.00US$110.00US$134.408
Sep ’24US$113.59
US$128.50
+13.1%
11.2%US$150.00US$110.00US$117.528
Aug ’24US$121.44
US$148.63
+22.4%
15.4%US$198.00US$120.00US$107.338
Jul ’24US$164.55
US$195.43
+18.8%
9.9%US$213.00US$150.00US$116.407
Jun ’24US$165.32
US$195.43
+18.2%
9.9%US$213.00US$150.00US$124.507
May ’24US$189.06
US$190.00
+0.5%
8.7%US$200.00US$150.00US$134.017
Apr ’24US$184.54
US$188.13
+1.9%
8.2%US$200.00US$150.00US$144.838
Mar ’24US$175.93
US$188.13
+6.9%
8.2%US$200.00US$150.00US$126.498
Feb ’24US$171.32
US$166.14
-3.0%
9.0%US$180.00US$135.00US$133.327
Jan ’24US$147.95
US$165.29
+11.7%
9.0%US$180.00US$135.00US$117.217
Dec ’23US$145.74
US$155.67
+6.8%
8.8%US$180.00US$135.00US$96.716
Nov ’23US$131.63
US$175.33
+33.2%
9.7%US$206.00US$150.00US$78.576
Oct ’23US$141.16
US$174.40
+23.5%
10.6%US$206.00US$150.00US$87.685

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies